Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...

Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...

The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

TORONTO, ON / ACCESS Newswire / February 24, 2025 / AmeriTrust Financial Technologies Inc. ("AmeriTrust" or the "Company"), a fintech platform targeting automotive finance and specializing in used ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on ...